Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to partici...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/1/165 |
| _version_ | 1827628246826483712 |
|---|---|
| author | Irene Persano Massimiliano Cani Benedetta Del Rio Giorgia Ferrari Edoardo Garbo Elena Parlagreco Chiara Pisano Valeria Cetoretta Marco Donatello Delcuratolo Fabio Turco Alessandro Audisio Cristina Cecchi Gianmarco Leone Valerio Maria Napoli Valentina Bertaglia Valentina Bianco Enrica Capelletto Carmen D’Amiano Massimo Di Maio Martina Gianetta Silvia Novello Francesco Passiglia Giorgio Vittorio Scagliotti Paolo Bironzo |
| author_facet | Irene Persano Massimiliano Cani Benedetta Del Rio Giorgia Ferrari Edoardo Garbo Elena Parlagreco Chiara Pisano Valeria Cetoretta Marco Donatello Delcuratolo Fabio Turco Alessandro Audisio Cristina Cecchi Gianmarco Leone Valerio Maria Napoli Valentina Bertaglia Valentina Bianco Enrica Capelletto Carmen D’Amiano Massimo Di Maio Martina Gianetta Silvia Novello Francesco Passiglia Giorgio Vittorio Scagliotti Paolo Bironzo |
| author_sort | Irene Persano |
| collection | DOAJ |
| description | Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life. |
| first_indexed | 2024-03-09T13:29:00Z |
| format | Article |
| id | doaj.art-2e63b9cd60f041349dda710a43ca1131 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T13:29:00Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-2e63b9cd60f041349dda710a43ca11312023-11-30T21:20:24ZengMDPI AGBiomedicines2227-90592023-01-0111116510.3390/biomedicines11010165Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center ExperienceIrene Persano0Massimiliano Cani1Benedetta Del Rio2Giorgia Ferrari3Edoardo Garbo4Elena Parlagreco5Chiara Pisano6Valeria Cetoretta7Marco Donatello Delcuratolo8Fabio Turco9Alessandro Audisio10Cristina Cecchi11Gianmarco Leone12Valerio Maria Napoli13Valentina Bertaglia14Valentina Bianco15Enrica Capelletto16Carmen D’Amiano17Massimo Di Maio18Martina Gianetta19Silvia Novello20Francesco Passiglia21Giorgio Vittorio Scagliotti22Paolo Bironzo23Department of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, Mauriziano Hospital, 10128 Torino, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, ItalySafety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life.https://www.mdpi.com/2227-9059/11/1/165COVID-19 pandemicSARS-CoV-2 infectionprevention strategiesCOVID-19 vaccinationcancer patientspatients reported outcomes |
| spellingShingle | Irene Persano Massimiliano Cani Benedetta Del Rio Giorgia Ferrari Edoardo Garbo Elena Parlagreco Chiara Pisano Valeria Cetoretta Marco Donatello Delcuratolo Fabio Turco Alessandro Audisio Cristina Cecchi Gianmarco Leone Valerio Maria Napoli Valentina Bertaglia Valentina Bianco Enrica Capelletto Carmen D’Amiano Massimo Di Maio Martina Gianetta Silvia Novello Francesco Passiglia Giorgio Vittorio Scagliotti Paolo Bironzo Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience Biomedicines COVID-19 pandemic SARS-CoV-2 infection prevention strategies COVID-19 vaccination cancer patients patients reported outcomes |
| title | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
| title_full | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
| title_fullStr | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
| title_full_unstemmed | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
| title_short | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
| title_sort | short term safety and psychosocial impact of the bnt162b2 mrna covid 19 vaccine in cancer patients an italian single center experience |
| topic | COVID-19 pandemic SARS-CoV-2 infection prevention strategies COVID-19 vaccination cancer patients patients reported outcomes |
| url | https://www.mdpi.com/2227-9059/11/1/165 |
| work_keys_str_mv | AT irenepersano shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT massimilianocani shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT benedettadelrio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT giorgiaferrari shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT edoardogarbo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT elenaparlagreco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT chiarapisano shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT valeriacetoretta shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT marcodonatellodelcuratolo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT fabioturco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT alessandroaudisio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT cristinacecchi shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT gianmarcoleone shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT valeriomarianapoli shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT valentinabertaglia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT valentinabianco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT enricacapelletto shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT carmendamiano shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT massimodimaio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT martinagianetta shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT silvianovello shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT francescopassiglia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT giorgiovittorioscagliotti shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT paolobironzo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience |